Q3 2026 McKesson Corp Earnings Call Transcript
Key Points
- McKesson Corp (MCK) reported double-digit growth in revenue and adjusted EPS, driven by strong performance in oncology, biopharma services, and North American distribution.
- The company raised its full-year EPS guidance to a range of $38.80 to $39.20, reflecting 17 to 19% year-over-year growth.
- McKesson's oncology and multi-specialty business continues to expand, with significant contributions from the integration of Florida Cancer Specialists and Prism Vision.
- The biopharma services platform added over 50 new programs across 43 unique brands, highlighting strong demand for access and affordability solutions.
- McKesson is investing in technology and automation to improve efficiency, with AI tools enhancing customer service and operational productivity.
- Operating expenses increased by 7% to $2.1 billion, reflecting higher costs in growth platforms and acquisitions.
- The medical surgical solutions segment saw a 10% decrease in operating profit due to lower volumes in physician office settings and a mild illness season.
- The company faces variability in revenue and operating profit trends in the prescription technology solutions segment due to factors like product launches and supply chain dynamics.
- McKesson's separation of the medical surgical business is ongoing, with an IPO planned for the second half of 2027, subject to market conditions.
- The company is navigating a dynamic policy landscape, including the Inflation Reduction Act and other regulatory changes, which could impact future operations.
Please stand by.
Welcome to McKesson's 3rd quarter fiscal 2026 earnings conference call.
Please be advised that today's conference is being recorded. At this time, I would like to turn the call over to Jenny Dominguez, VP of Investor relations. Please go ahead.
Thank you, operator. Good afternoon and welcome everyone to McEson's 3rd quarter fiscal 2026 earnings call.
Today I'm joined by Brian Tyler, our Chief Executive Officer, and Britt Vilo, our Chief Financial Officer.
Brian will be off, followed by Britt, and then we'll move to a question-and-answer session.
Today's discussion will include forward-looking statements.
Such as forecasts about McKesson's operations and future results, please refer to the cautionary statements in today's earnings release.
In presentation slides available on our website at investor.mcesson.com and the risk factors section of our most recent annual and periodic SEC filings for additional information
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
